Publication Database

The stratum corneum is the target of CMS nanocarriers after topical application in healthy and inflamed mouse skin (2016)

Art

Vortrag

Autoren

Radbruch, M (WE 12)

Pischon, H (WE 12)

Ostrowski, A (WE 12)

Unbehauen, M

Volz, P

Alexiev, U

Haag, R

Gruber, A.D. (WE 12)

Mundhenk, L (WE 12)

Kongress

Int.Conference on Dermal Drug Delivery by Nanocarriers 2016

Berlin, Deutschland, 14. – 16.03.2016

Quelle

Nanomedicine : nanotechnology, biology, and medicine

Bandzählung: 13

Heftzählung: 1

Seiten: 317 – 327

ISSN: 1549-9642

Sprache

Englisch

Verweise

DOI: 10.1016/j.nano.2016.09.004

Kontakt

Institut für Tierpathologie

Robert-von-Ostertag-Str. 15
14163 Berlin
+49 30 838 62450
pathologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Inflammatory disorders of the skin pose particular therapeutic challenges due to complex structural and functional alterations of the skin barrier. Penetration of several anti-inflammatory drugs is particularly problematic in psoriasis, a common dermatitis condition with epidermal hyperplasia and hyperkeratosis. Here, we tested in vivo dermal penetration and biological effects of dendritic core-multishell-nanocarriers (CMS) in a murine skin model of psoriasis and compared it to healthy skin. In both groups, CMS exclusively localized to the stratum corneum of the epidermis with only very sporadic uptake by Langerhans cells. Furthermore, penetration into the viable epidermis of nile red as a model for lipophilic compounds was enhanced by CMS. CMS proved fully biocompatible in several in vitro assays and on normal and psoriatic mouse skin. The observations support the concept of CMS as promising candidates for drug delivery in inflammatory hyperkeratotic skin disorders in vivo.